{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:11:31Z","timestamp":1789031491179,"version":"build-2803163510"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:p>\n                    Hemophilia is an X-linked hereditary bleeding disorder caused by loss-of-function mutations in the genes encoding coagulation factors, leading to excessive bleeding and potentially being life-threatening. Currently, regular treatment for hemophilia is the infusion of recombinant blood coagulation factors. This approach is not only costly but can also give rise to complications such as the development of neutralizing antibodies (Nabs), which impede the therapeutic outcome. Hemophilia is a monogenic disease, making gene therapy a promising curative measure that includes gene addition and gene editing approaches. Adeno-associated virus (AAV) vectors have gained massive attention as the premier delivery vehicle for clinical gene therapy due to their diverse tissue tropisms dictated by the natural and engineered AAV capsids, their excellent safety profile since AAVs do not cause any known human diseases, low immunogenicity, and long-lasting gene expression. Several AAV-based gene addition therapies have been approved for hemophilia B and hemophilia A, and dozens of similar AAV-based clinical trials are underway. Gene editing technologies, like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)\/CRISPR-associated protein 9 (Cas9), have shown immense potential in the treatment of genetic diseases. CRISPR\/Cas9-mediated transgene integration provides critical advantages over regular gene insertion therapy by enabling site-specific, targeted genomic integration rather than random integration. Clinical trials focusing on AAV-CRISPR\/Cas9-mediated knock-in of human genes represent the frontier of\n                    <jats:italic>in vivo<\/jats:italic>\n                    genetic medicine, and one such prominent ongoing clinical trial for hemophilia B is designed to insert the human Factor IX gene into hepatocytes. This review outlines recent advances and feasible strategies of CRISPR\/Cas9-based genome editing for hemophilia therapy, highlights the potential applications of next-generation gene editing and vector delivery technologies, and offers new insights for the advantages, limitations, and future directions for these novel treatment modalities.\n                  <\/jats:p>","DOI":"10.3389\/fgeed.2026.1924733","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:03:12Z","timestamp":1789030992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in CRISPR-based in vivo gene therapy for hemophilia"],"prefix":"10.3389","volume":"8","author":[{"given":"Xiaoyu","family":"Zhang","sequence":"first","affiliation":[{"name":"The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University","place":["Changchun, China"]},{"name":"The Third Norman Bethune Clinical College of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidi","family":"Xu","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changchun People\u2019s Hospital","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University","place":["Changchun, China"]},{"name":"The Third Norman Bethune Clinical College of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhi","family":"Teng","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood.2024027870","article-title":"Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B","volume":"147","author":"Baatartsogt","year":"2026","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood.2023022589","article-title":"Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer","volume":"143","author":"Batty","year":"2024","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1016\/j.ymthe.2024.09.032","article-title":"AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription","volume":"32","author":"Bazick","year":"2024","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3324\/haematol.2019.224063","article-title":"CRISPR\/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs","volume":"106","author":"Chen","year":"","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins","volume":"12","author":"Chen","year":"","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104414","DOI":"10.1016\/j.isci.2022.104414","article-title":"Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin","volume":"25","author":"Chen","year":"","journal-title":"iScience"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jgg.2022.06.001","article-title":"Long-term correction of hemophilia B through CRISPR\/Cas9 induced homology-independent targeted integration","volume":"49","author":"Chen","year":"","journal-title":"J. Genet. Genomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41587-023-01821-9","article-title":"Adenine transversion editors enable precise, efficient A*T-to-C*G base editing in mammalian cells and embryos","volume":"42","author":"Chen","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.omtn.2024.102383","article-title":"Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs","volume":"35","author":"Chen","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1408","DOI":"10.1002\/wsbm.1408","article-title":"Immunity to CRISPR Cas9 and Cas12a therapeutics","volume":"10","author":"Chew","year":"2018","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat. Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMc2415164","article-title":"Platelet-targeted gene therapy for hemophilia A with inhibitor history","volume":"392","author":"Eapen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.xcrm.2024.101619","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.omtn.2018.12.008","article-title":"Viral vector-based delivery of CRISPR\/Cas9 and donor DNA for homology-directed repair in an in vitro model for canine hemophilia B","volume":"14","author":"Gao","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nbt.4199","article-title":"An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities","volume":"36","author":"Gehrke","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman Primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.14337","article-title":"Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A","volume":"17","author":"Girard","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"B42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.transci.2019.08.012","article-title":"Gene therapy for hemophilia: progress to date and challenges moving forward","volume":"58","author":"Gollomp","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201506039","article-title":"CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse","volume":"8","author":"Guan","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nbt.2909","article-title":"Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification","volume":"32","author":"Guilinger","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"eabj6901","DOI":"10.1126\/sciadv.abj6901","article-title":"In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci. Adv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"102050","DOI":"10.1016\/j.omtn.2023.102050","article-title":"In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice","volume":"34","author":"Han","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9157","DOI":"10.1038\/s41467-025-64181-9","article-title":"Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery","volume":"16","author":"Han","year":"2025","journal-title":"Nat. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia - from basic science to first approvals of one-and-done therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s43856-023-00286-w","article-title":"PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells","volume":"3","author":"Hiramoto","year":"2023","journal-title":"Commun. Med. (Lond)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1115831","DOI":"10.3389\/fgene.2023.1115831","article-title":"Correction of F8 intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR\/Cas9 mediated gene editing","volume":"14","author":"Hu","year":"2023","journal-title":"Front. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41587-019-0134-y","article-title":"Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors","volume":"37","author":"Huang","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0065-2660(08)60144-3","article-title":"DNA breakage and repair","volume":"38","author":"Jeggo","year":"1998","journal-title":"Adv. Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2020.07.005","article-title":"Rationally designed APOBEC3B cytosine base editors with improved specificity","volume":"79","author":"Jin","year":"2020","journal-title":"Mol. Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1160\/th13-02-0154","article-title":"Incorporation of the factor IX padua mutation into FIX-triple improves clotting activity in vitro and in vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb. Haemost."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","article-title":"Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions","volume":"35","author":"Kim","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s12276-024-01375-z","article-title":"Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCs","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nbt.4172","article-title":"Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction","volume":"36","author":"Koblan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"eaao4774","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","author":"Komor","year":"2017","journal-title":"Sci. Adv."},{"key":"B67","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41587-022-01611-9","article-title":"Improved cytosine base editors generated from TadA variants","volume":"41","author":"Lam","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.omtn.2022.08.002","article-title":"Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia","volume":"29","author":"Lee","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B71","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41467-022-29339-9","article-title":"Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1538-7836.2010.03913.x","article-title":"Generation of a novel factor IX with augmented clotting activities in vitro and in vivo","volume":"8","author":"Lin","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B77","doi-asserted-by":"publisher","first-page":"785698","DOI":"10.3389\/fgeed.2022.785698","article-title":"Promoterless gene targeting approach combined to CRISPR\/Cas9 efficiently corrects hemophilia B phenotype in neonatal mice","volume":"4","author":"Lisjak","year":"2022","journal-title":"Front. Genome"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41587-022-01255-9","article-title":"A split prime editor with untethered reverse transcriptase and circular RNA template","volume":"40","author":"Liu","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ymthe.2025.09.001","article-title":"A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy","volume":"34","author":"Liu","year":"2025","journal-title":"Mol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/hep.32211","article-title":"In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model","volume":"75","author":"Luce","year":"2022","journal-title":"Hepatology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"672564","DOI":"10.3389\/fcell.2021.672564","article-title":"CRISPR\/Cas9-Mediated in vivo genetic correction in a mouse model of hemophilia A","volume":"9","author":"Luo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life10120366","article-title":"Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome editing","volume":"10","author":"Lyu","year":"2020","journal-title":"Life (Basel)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/nejm200106073442307","article-title":"Medical progress - the hemophilias - from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Adv."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cells9071608","article-title":"Latest developed strategies to minimize the off-target effects in CRISPR-Cas-Mediated genome editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells"},{"key":"B89","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","article-title":"Engineered pegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","article-title":"Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity","volume":"41","author":"Neugebauer","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1126\/science.aas9129","article-title":"Engineered CRISPR-Cas9 nuclease with expanded targeting space","volume":"361","author":"Nishimasu","year":"2018","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/s41598-017-04625-5","article-title":"CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice","volume":"7","author":"Ohmori","year":"2017","journal-title":"Sci. Rep."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02855-x","article-title":"Elucidating lipid nanoparticle properties and structure through biophysical analyses","author":"Padilla","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/mt.2016.38","article-title":"Gene insertion into genomic safe harbors for human gene therapy","volume":"24","author":"Papapetrou","year":"2016","journal-title":"Mol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00018-009-8740-3","article-title":"DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship","volume":"66","author":"Pardo","year":"2009","journal-title":"Cell Mol. Life Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1073\/pnas.1323941111","article-title":"Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs","volume":"111","author":"Park","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e2201095","DOI":"10.1002\/adma.202201095","article-title":"Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system","volume":"34","author":"Pattipeiluhu","year":"2022","journal-title":"Adv. Mater"},{"key":"B99","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","article-title":"Targeting anticoagulant protein S to improve hemostasis in hemophilia","volume":"131","author":"Prince","year":"2018","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/asheducation-2017.1.605","article-title":"Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy","volume":"2017","author":"Ragni","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2021.01.002","article-title":"The evolution and history of gene editing technologies","volume":"178","author":"Randhawa","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"B106","volume-title":"Global Survey","year":"2026"},{"key":"B107","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","article-title":"The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality","volume":"13","author":"Rodriguez-Merchan","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.3390\/ijms22147647","article-title":"Gene therapy in hemophilia: recent advances","volume":"22","author":"Rodr\u00edguez-Merch\u00e1n","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"B111","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.thromres.2024.04.031","article-title":"AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B","volume":"238","author":"Sarangi","year":"2024","journal-title":"Thromb. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat. Methods"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"Siner","year":"2013","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.1128\/jvi.00751-10","article-title":"Chromosomal integration of adenoviral vector DNA in vivo","volume":"84","author":"Stephen","year":"2010","journal-title":"J. Virol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9","volume":"298","author":"Stephens","year":"2019","journal-title":"J. Control Release"},{"key":"B121","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41587-023-01769-w","article-title":"Precise integration of large DNA sequences in plant genomes using PrimeRoot editors","volume":"42","author":"Sun","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"B123","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41422-019-0213-0","article-title":"Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction","volume":"29","author":"Suzuki","year":"2019","journal-title":"Cell Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41467-018-08034-8","article-title":"Engineering of high-precision base editors for site-specific single nucleotide replacement","volume":"10","author":"Tan","year":"2019","journal-title":"Nat. Commun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41587-019-0193-0","article-title":"Continuous evolution of base editors with expanded target compatibility and improved activity","volume":"37","author":"Thuronyi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.jtha.2024.04.020","article-title":"DNA base editing corrects common hemophilia A mutations and restores factor VIII expression in in vitro and ex vivo models","volume":"22","author":"Tonetto","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41587-022-01595-6","article-title":"Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase","volume":"41","author":"Tong","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/312342a0","article-title":"Molecular cloning of a cDNA encoding human antihaemophilic factor","volume":"312","author":"Toole","year":"1984","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"Van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molcel.2016.06.037","article-title":"DNA repair profiling reveals nonrandom outcomes at Cas9-Mediated breaks","volume":"63","author":"Van Overbeek","year":"2016","journal-title":"Mol. Cell"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aba8853","article-title":"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants","volume":"368","author":"Walton","year":"2020","journal-title":"Science"},{"key":"B134","doi-asserted-by":"publisher","first-page":"eabp9435","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci. Adv."},{"key":"B135","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"","journal-title":"Nat. Rev. Drug Discov."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-Mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e2110887118","DOI":"10.1073\/pnas.2110887118","article-title":"Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV\/CRISPR infusion","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B139","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-Binding protein","volume":"628","author":"Yan","year":"2024","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"B142","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/cr.2017.76","article-title":"Homology-mediated end joining-based targeted integration using CRISPR\/Cas9","volume":"27","author":"Yao","year":"2017","journal-title":"Cell Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/nbt.4194","article-title":"Optimized base editors enable efficient editing in cells, organoids and mice","volume":"36","author":"Zafra","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/srep05405","article-title":"Comparison of non-canonical PAMs for CRISPR\/Cas9-mediated DNA cleavage in human cells","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"B146","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13059-019-1907-9","article-title":"Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse","volume":"20","author":"Zhang","year":"2019","journal-title":"Genome Biol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41556-020-0518-8","article-title":"Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain","volume":"22","author":"Zhang","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.stem.2024.04.022","article-title":"Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases","volume":"31","author":"Zhang","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B149","doi-asserted-by":"publisher","first-page":"114141","DOI":"10.1016\/j.jconrel.2025.114141","article-title":"Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A","volume":"386","author":"Zhao","year":"2025","journal-title":"J. Control Release"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-023-39137-6","article-title":"Template-jumping prime editing enables large insertion and exon rewriting in vivo","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat. Commun."},{"key":"B151","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-019-1314-0","article-title":"Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis","volume":"571","author":"Zhou","year":"2019","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03227-9","article-title":"Efficient in vivo cytosine base editing using virus-like particles with uracil DNA glycosylase inhibition","author":"Zhu","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"key":"B154","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41592-020-0832-x","article-title":"A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects","volume":"17","author":"Zuo","year":"2020","journal-title":"Nat. Methods"}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1924733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:03:13Z","timestamp":1789030993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1924733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":154,"alternative-id":["10.3389\/fgeed.2026.1924733"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2026.1924733","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1924733"}}